Posted by Michael Wonder on 18 Jan 2023
BeiGene announces expansion of coverage on China’s National Reimbursement Drug List
18 January 2023 - Four new indications added for tislelizumab and all nine approved indications now included in National Reimbursement Drug List.
BeiGene today announced that the National Reimbursement Drug List released by China’s National Healthcare Security Administration has been updated to include four new indications for its PD-1 inhibitor tislelizumab.
Kyprolis (carfilzomib), a proteosome inhibitor licensed-in from Amgen, is included for the first time and Xgeva (denosumab), a RANKL inhibitor and another Amgen asset, successfully renewed this year.
The updated National Reimbursement Drug List will officially take effect on 1 March 2023.
